Aspirin for in vitro fertilisation

摘要: Background Aspirin is used with the aim of optimising chance live birth in women undergoing assisted reproductive technology (ART), despite inconsistent evidence its efficacy and safety (in terms intraoperative bleeding during oocyte retrieval risk miscarriage). The most appropriate time to commence aspirin therapy length treatment required are also still be determined. This second update review first published 2007. Objectives To evaluate effectiveness ART. Search methods We searched Cochrane Gynaecology Fertility Group Trials Register, Central Register Controlled (CENTRAL; 2016, Issue 4) Library (searched 9 May 2016); databases MEDLINE (1946 2016) Embase (1974 trial registers (ClinicalTrials.gov World Health Organization International Clinical Registry Platform search portal). We examined reference lists all known primary studies articles, citation relevant publications abstracts major scientific meetings, combined Group's strategy. Selection criteria Randomised controlled trials on for ART. Data collection analysis Two authors independently assessed eligibility bias extracted data. outcome was birth. Secondary outcomes included clinical pregnancy, ongoing multiple miscarriage, other complications associated IVF/ICSI or pregnancy data calculate ratios (RRs) (for dichotomous data) mean differences (MDs) continuous 95% confidence intervals (CIs). Statistical heterogeneity using I² statistic. overall quality main comparisons GRADE methods. Main results The identified 13 as eligible inclusion review, including a total 2653 participants age 35 years. Ten dose 100 mg three 80 per day. In them, commenced immediately at start down-regulation, while duration varied widely. Eight provided placebo control group. There no difference between group receiving rates (RR 0.91, CI 0.72 1.15, 3 RCTs, n = 1053, 15%, moderate-quality evidence). addition, were similar two groups 1.03, 0.91 1.17, 10 2142, 27%, evidence); sensitivity analysis, excluding high bias, did not change effect estimate. There confirmed by ultrasound 0.67, 0.37 1.25, 2 656, 0%, low-quality evidence), miscarriage 1.10, 0.68 1.77, 5 1497, ectopic 1.86, 0.75 4.63, 1135, very low evidence) vaginal 1.01, 0.14 7.13, 1 RCT, 487, Data lacking adverse effects. The ranged from moderate; limitations poor reporting study methods suspected publication bias. Authors' conclusions Currently there favour routine use order improve general IVF population. based available randomised trials, where currently an ART, single measure demonstrating benefit use. Furthermore, current does exclude possibility effects.